TAS 106

Drug Profile

TAS 106

Alternative Names: ECyd; Ethynylcytidine; SB 596168; TAS-106

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine triphosphate synthetase inhibitors; DNA-directed RNA polymerase inhibitors; Ribonucleotide reductase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Solid tumours

Most Recent Events

  • 30 Sep 2011 Phase-I/II clinical trials in Solid tumours in USA (IV)
  • 05 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Onclology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,
  • 29 Dec 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top